Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Current Deferred Revenue: 2017-2018

Historic Current Deferred Revenue for UroGen Pharma (URGN) over the last 1 years, with Jun 2018 value amounting to $86,000.

  • UroGen Pharma's Current Deferred Revenue fell 72.35% to $86,000 in Q2 2018 from the same period last year, while for Jun 2018 it was $86,000, marking a year-over-year decrease of 72.35%. This contributed to the annual value of $650,000 for FY2017, which is N/A change from last year.
  • According to the latest figures from Q2 2018, UroGen Pharma's Current Deferred Revenue is $86,000, which was down 56.12% from $196,000 recorded in Q1 2018.
  • UroGen Pharma's Current Deferred Revenue's 5-year high stood at $650,000 during Q4 2017, with a 5-year trough of $86,000 in Q2 2018.
  • Over the past 2 years, UroGen Pharma's median Current Deferred Revenue value was $300,000 (recorded in 2017), while the average stood at $308,600.
  • Data for UroGen Pharma's Current Deferred Revenue shows a maximum YoY plummeted of 72.35% (in 2018) over the last 5 years.
  • UroGen Pharma's Current Deferred Revenue (Quarterly) stood at $650,000 in 2017, then tumbled by 72.35% to $86,000 in 2018.
  • Its last three reported values are $86,000 in Q2 2018, $196,000 for Q1 2018, and $650,000 during Q4 2017.